"Nicotinic Agonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that bind to and activate nicotinic cholinergic receptors (RECEPTORS, NICOTINIC). Nicotinic agonists act at postganglionic nicotinic receptors, at neuroeffector junctions in the peripheral nervous system, and at nicotinic receptors in the central nervous system. Agents that function as neuromuscular depolarizing blocking agents are included here because they activate nicotinic receptors, although they are used clinically to block nicotinic transmission.
Descriptor ID |
D018722
|
MeSH Number(s) |
D27.505.519.625.120.140.700 D27.505.696.577.120.140.700
|
Concept/Terms |
Nicotinic Agonists- Nicotinic Agonists
- Agonists, Nicotinic
- Cholinergic Agonists, Nicotinic
- Agonists, Nicotinic Cholinergic
- Nicotinic Cholinergic Agonists
- Nicotinic Agonist
- Agonist, Nicotinic
- Cholinergic Agonist, Nicotinic
- Agonist, Nicotinic Cholinergic
- Nicotinic Cholinergic Agonist
|
Below are MeSH descriptors whose meaning is more general than "Nicotinic Agonists".
Below are MeSH descriptors whose meaning is more specific than "Nicotinic Agonists".
This graph shows the total number of publications written about "Nicotinic Agonists" by people in this website by year, and whether "Nicotinic Agonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2003 | 1 | 0 | 1 |
2007 | 0 | 1 | 1 |
2008 | 0 | 1 | 1 |
2009 | 0 | 1 | 1 |
2011 | 0 | 1 | 1 |
2014 | 0 | 1 | 1 |
2016 | 0 | 1 | 1 |
2017 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Nicotinic Agonists" by people in Profiles.
-
Vicary GW, Ritzenthaler JD, Panchabhai TS, Torres-González E, Roman J. Nicotine stimulates collagen type I expression in lung via a7 nicotinic acetylcholine receptors. Respir Res. 2017 06 02; 18(1):115.
-
Gopalakrishna G, Ithman MH, Lauriello J. Update on New and Emerging Treatments for Schizophrenia. Psychiatr Clin North Am. 2016 06; 39(2):217-38.
-
Paul RK, Singh NS, Khadeer M, Moaddel R, Sanghvi M, Green CE, O'Loughlin K, Torjman MC, Bernier M, Wainer IW. (R,S)-Ketamine metabolites (R,S)-norketamine and (2S,6S)-hydroxynorketamine increase the mammalian target of rapamycin function. Anesthesiology. 2014 Jul; 121(1):149-59.
-
Seder DB, Schmidt JM, Badjatia N, Fernandez L, Rincon F, Claassen J, Gordon E, Carrera E, Kurtz P, Lee K, Connolly ES, Mayer SA. Transdermal nicotine replacement therapy in cigarette smokers with acute subarachnoid hemorrhage. Neurocrit Care. 2011 Feb; 14(1):77-83.
-
Hruska M, Keefe J, Wert D, Tekinay AB, Hulce JJ, Ibañez-Tallon I, Nishi R. Prostate stem cell antigen is an endogenous lynx1-like prototoxin that antagonizes alpha7-containing nicotinic receptors and prevents programmed cell death of parasympathetic neurons. J Neurosci. 2009 Nov 25; 29(47):14847-54.
-
Kozuch PL, Hanauer SB. Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol. 2008 Jan 21; 14(3):354-77.
-
Kulak JM, Fan H, Schneider JS. Beta2* and beta4* nicotinic acetylcholine receptor expression changes with progressive parkinsonism in non-human primates. Neurobiol Dis. 2007 Sep; 27(3):312-9.
-
Tosaka T, Casimiro MC, Rong Q, Tella S, Oh M, Katchman AN, Pezzullo JC, Pfeifer K, Ebert SN. Nicotine induces a long QT phenotype in Kcnq1-deficient mouse hearts. J Pharmacol Exp Ther. 2003 Sep; 306(3):980-7.